{
    "info": {
        "nct_id": "NCT03565783",
        "official_title": "Phase II Study of REGN2810 Prior to Surgery in Patients With Stage II-IV Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck",
        "inclusion_criteria": "* Biopsy-proven, primary or recurrent stage II-IV cutaneous squamous cell carcinoma of the head and neck.\n* Surgical resection must be planned as primary therapy with or without adjuvant radiation therapy. Patients are eligible with previous surgical intervention if they have residual or recurrent disease, and it is greater than 4 weeks since surgery and they have fully recovered from surgery.\n* Signed informed consent form (ICF).*\n* Ability and willingness to comply with the requirements of the study protocol.*\n* Age >= 18 years.\n* Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 4 weeks [+/-3 days] prior to study entry).\n* White blood cell (WBC) counts >= 2500/uL (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Lymphocyte count >= 300/uL (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Platelet count >= 100,000uL for patients with hematologic malignancies, platelet count >= 75,000/uL (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Hemoglobin >= 9.0 g/dL (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) with the following exception: patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Alkaline phosphatase =< 2.5 x ULN with the following exception: patients with documented bone metastases: alkaline phosphatase =< 5 x ULN (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation (obtained within 4 weeks [+/-3 days] prior to study entry).\n* Measurable disease per RECIST v1.1 and/or per direct clinical measurements for primary tumors upon a variance between clinical and radiographic evaluation.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation [such as low-molecular-weight heparin or warfarin] should be on a stable dose.)\n* No evidence of distant metastases and measurable disease (> 1.5 cm).\n\n  * Please Note:\n\nPatients may be enrolled regardless of their language. The ICD / translator SOP will be followed for Non-English speaking patients.\n\nCognitively-Impaired adults may be considered for this protocol. If so, the ICD / LAR SOP will be followed.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed: Hormone-replacement therapy; palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1.\n* Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia.\n* Bisphosphonate therapy for symptomatic hypercalcemia\n\n  * Use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowed.\n* Patients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma.\n* Pregnancy, lactation, or breastfeeding.\n* Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.\n* Inability to comply with study and follow-up procedures.\n* History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible.\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; Rash must cover less than 10% of body surface area (BSA); Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%); No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).\n* History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan.\n\n  * History of radiation pneumonitis in the radiation field [fibrosis] is permitted.\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.\n* History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic or acute) or hepatitis C infection.\n\n  * Patients with past or resolved hepatitis B infection; defined as having a negative hepatitis B surface antigen (HBsAg) test and a positive anti-HBc (antibody to hepatitis B core antigen) antibody test, are eligible.\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).\n* Active tuberculosis.\n* Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Signs or symptoms of infection as determined by the treating team within 2 weeks prior to cycle 1, day 1.\n* Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\n\n  * Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.\n* Major surgical procedure within 28 days prior to cycle 1, day 1.\n* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study.\n\n  * Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study.\n* Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)\n* Continued sexual activity in men** or women of childbearing potential*** who are unwilling to practice highly effective contraception during the study and until 6 months after the last dose of study drug (highly effective contraceptive measures include stable use of oral contraceptives such as combined estrogen and progestogen and progestogen only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; intrauterine hormone-releasing system [IUS]; bilateral tubal ligation; vasectomy, and sexual abstinence). (**Contraception is not required for men with documented vasectomy ***Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.)\n* Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents. Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).\n* Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN] or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1.\n* Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer).\n* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1.\n\n  * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.\n  * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation.\n* Patients with prior treatment with idelalisib.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Hemoglobin >= 9.0 g/dL (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation [such as low-molecular-weight heparin or warfarin] should be on a stable dose.)",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ... =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "therapeutic anticoagulation status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "therapeutic anticoagulation status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients receiving therapeutic anticoagulation [such as low-molecular-weight heparin or warfarin] should be on a stable dose",
                    "criterion": "therapeutic anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "medication stability",
                            "expected_value": "stable dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed informed consent form (ICF).*",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent form (ICF)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... =< 3.0 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 3.0 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation",
                    "criterion": "creatinine clearance (Cockcroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500 cells/uL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Biopsy-proven, primary or recurrent stage II-IV cutaneous squamous cell carcinoma of the head and neck.",
            "criterions": [
                {
                    "exact_snippets": "Biopsy-proven",
                    "criterion": "diagnosis confirmation by biopsy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "primary or recurrent",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "primary",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "stage II-IV",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cutaneous squamous cell carcinoma",
                    "criterion": "histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "cutaneous squamous cell carcinoma"
                        }
                    ]
                },
                {
                    "exact_snippets": "of the head and neck",
                    "criterion": "tumor location",
                    "requirements": [
                        {
                            "requirement_type": "anatomic location",
                            "expected_value": "head and neck"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No evidence of distant metastases and measurable disease (> 1.5 cm).",
            "criterions": [
                {
                    "exact_snippets": "No evidence of distant metastases",
                    "criterion": "distant metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease (> 1.5 cm)",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients may be enrolled regardless of their language. The ICD / translator SOP will be followed for Non-English speaking patients.",
            "criterions": [
                {
                    "exact_snippets": "Patients may be enrolled regardless of their language.",
                    "criterion": "language",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cell (WBC) counts >= 2500/uL (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "White blood cell (WBC) counts >= 2500/uL",
                    "criterion": "white blood cell (WBC) count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2500,
                                "unit": "/uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase =< 2.5 x ULN with the following exception: patients with documented bone metastases: alkaline phosphatase =< 5 x ULN (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase =< 2.5 x ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with documented bone metastases: alkaline phosphatase =< 5 x ULN",
                    "criterion": "alkaline phosphatase (in patients with documented bone metastases)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained within 4 weeks [+/-3 days] prior to study entry",
                    "criterion": "alkaline phosphatase measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 4 weeks [+/-3 days] prior to study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability and willingness to comply with the requirements of the study protocol.*",
            "criterions": [
                {
                    "exact_snippets": "Ability ... to comply with the requirements of the study protocol",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to comply with the requirements of the study protocol",
                    "criterion": "willingness to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cognitively-Impaired adults may be considered for this protocol. If so, the ICD / LAR SOP will be followed.",
            "criterions": [
                {
                    "exact_snippets": "Cognitively-Impaired adults may be considered for this protocol.",
                    "criterion": "cognitive impairment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN) with the following exception: patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled",
                    "criterion": "serum bilirubin (in patients with known Gilbert disease)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained within 4 weeks [+/-3 days] prior to study entry",
                    "criterion": "timing of bilirubin measurement",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 4 weeks (+/-3 days) prior to study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgical resection must be planned as primary therapy with or without adjuvant radiation therapy. Patients are eligible with previous surgical intervention if they have residual or recurrent disease, and it is greater than 4 weeks since surgery and they have fully recovered from surgery.",
            "criterions": [
                {
                    "exact_snippets": "Surgical resection must be planned as primary therapy",
                    "criterion": "surgical resection as primary therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without adjuvant radiation therapy",
                    "criterion": "adjuvant radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": "optional"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients are eligible with previous surgical intervention if they have residual or recurrent disease",
                    "criterion": "residual or recurrent disease after previous surgical intervention",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "it is greater than 4 weeks since surgery",
                    "criterion": "time since previous surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "they have fully recovered from surgery",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "fully recovered"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lymphocyte count >= 300/uL (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Lymphocyte count >= 300/uL",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained within 4 weeks [+/-3 days] prior to study entry",
                    "criterion": "lymphocyte count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 4 weeks [+/-3 days] prior to study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000uL for patients with hematologic malignancies, platelet count >= 75,000/uL (obtained within 4 weeks [+/-3 days] prior to study entry).",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000uL for patients with hematologic malignancies",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        },
                        {
                            "requirement_type": "applicable_condition",
                            "expected_value": "hematologic malignancies"
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet count >= 75,000/uL (obtained within 4 weeks [+/-3 days] prior to study entry)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "uL"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "obtained within 4 weeks [+/-3 days] prior to study entry"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active tuberculosis.",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of radiation pneumonitis in the radiation field [fibrosis] is permitted.",
            "criterions": [
                {
                    "exact_snippets": "History of radiation pneumonitis in the radiation field [fibrosis] is permitted.",
                    "criterion": "history of radiation pneumonitis in the radiation field [fibrosis]",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy, lactation, or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bisphosphonate therapy for symptomatic hypercalcemia",
            "criterions": [
                {
                    "exact_snippets": "Bisphosphonate therapy for symptomatic hypercalcemia",
                    "criterion": "bisphosphonate therapy",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": "symptomatic hypercalcemia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.",
                    "criterion": "receipt of acute, low dose, systemic immunosuppressant medications",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "acute, low dose"
                        },
                        {
                            "requirement_type": "route",
                            "expected_value": "systemic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signs or symptoms of infection as determined by the treating team within 2 weeks prior to cycle 1, day 1.",
            "criterions": [
                {
                    "exact_snippets": "Signs or symptoms of infection as determined by the treating team within 2 weeks prior to cycle 1, day 1.",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving prophylactic antibiotics",
                    "criterion": "prophylactic antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for prevention of a urinary tract infection",
                    "criterion": "urinary tract infection prevention",
                    "requirements": [
                        {
                            "requirement_type": "purpose of antibiotic use",
                            "expected_value": "prevention of urinary tract infection"
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic obstructive pulmonary disease",
                    "criterion": "chronic obstructive pulmonary disease prevention",
                    "requirements": [
                        {
                            "requirement_type": "purpose of antibiotic use",
                            "expected_value": "prevention of chronic obstructive pulmonary disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed: Hormone-replacement therapy; palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1.",
            "criterions": [
                {
                    "exact_snippets": "Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment",
                    "criterion": "prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hormone-replacement therapy ... are allowed",
                    "criterion": "prior hormone-replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1 ... are allowed",
                    "criterion": "prior palliative radiotherapy for bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "allowed_if_time_since",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1.",
                    "criterion": "treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to cycle 1, day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; Rash must cover less than 10% of body surface area (BSA); Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%); No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).",
            "criterions": [
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded)",
                    "criterion": "dermatologic autoimmune conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "eczema",
                                "psoriasis",
                                "lichen simplex chronicus",
                                "vitiligo"
                            ]
                        },
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "baseline ophthalmologic exam",
                            "expected_value": "performed to rule out ocular manifestations"
                        }
                    ]
                },
                {
                    "exact_snippets": "Rash must cover less than 10% of body surface area (BSA)",
                    "criterion": "rash body surface area",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "% BSA"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)",
                    "criterion": "disease control and treatment",
                    "requirements": [
                        {
                            "requirement_type": "disease control",
                            "expected_value": "well controlled at baseline"
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "low potency topical steroids"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)",
                    "criterion": "acute exacerbations of underlying condition",
                    "requirements": [
                        {
                            "requirement_type": "exacerbation occurrence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within the last 12 months"
                        },
                        {
                            "requirement_type": "treatment escalation",
                            "expected_value": "not requiring PUVA, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to Chinese hamster ovary cell products",
                    "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... other recombinant human antibodies",
                    "criterion": "hypersensitivity to recombinant human antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure within 28 days prior to cycle 1, day 1.",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure within 28 days prior to cycle 1, day 1.",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days prior to cycle 1, day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",
            "criterions": [
                {
                    "exact_snippets": "Any other diseases ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",
                    "criterion": "other diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "metabolic dysfunction ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",
                    "criterion": "metabolic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "physical examination finding ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",
                    "criterion": "abnormal physical examination finding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical laboratory finding ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",
                    "criterion": "abnormal clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation.",
            "criterions": [
                {
                    "exact_snippets": "prior allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with prior treatment with idelalisib.",
            "criterions": [
                {
                    "exact_snippets": "prior treatment with idelalisib",
                    "criterion": "prior treatment with idelalisib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowed.",
                    "criterion": "bisphosphonate therapy for other reasons (e.g., osteoporosis)",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "other reasons",
                                "osteoporosis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1",
                    "criterion": "antibiotic administration",
                    "requirements": [
                        {
                            "requirement_type": "route of administration",
                            "expected_value": [
                                "oral",
                                "IV"
                            ]
                        },
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "reference timepoint",
                            "expected_value": "prior to cycle 1, day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.",
                    "criterion": "severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic or acute) or hepatitis C infection.",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B (chronic or acute)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": [
                                "chronic",
                                "acute"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).",
            "criterions": [
                {
                    "exact_snippets": "Patients positive for hepatitis C virus (HCV) antibody",
                    "criterion": "hepatitis C virus (HCV) antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)",
                    "criterion": "HCV ribonucleic acid (RNA) by PCR",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to comply with study and follow-up procedures.",
            "criterions": [
                {
                    "exact_snippets": "Inability to comply with study and follow-up procedures.",
                    "criterion": "ability to comply with study and follow-up procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study.",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before cycle 1, day 1",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live, attenuated vaccine will be required during the study",
                    "criterion": "anticipated requirement for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated requirement during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible.",
            "criterions": [
                {
                    "exact_snippets": "History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history or risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible",
                    "criterion": "autoimmune hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment stability",
                            "expected_value": "stable dose of thyroid replacement hormone"
                        }
                    ]
                },
                {
                    "exact_snippets": "controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible",
                    "criterion": "type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "disease control",
                            "expected_value": "controlled"
                        },
                        {
                            "requirement_type": "treatment stability",
                            "expected_value": "stable insulin regimen"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer).",
            "criterions": [
                {
                    "exact_snippets": "Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)",
                    "criterion": "treatment with investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study.",
            "criterions": [
                {
                    "exact_snippets": "Influenza vaccination should be given during influenza season only (approximately October to March)",
                    "criterion": "influenza vaccination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during influenza season only (approximately October to March)"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study",
                    "criterion": "live, attenuated influenza vaccine (e.g., FluMist)",
                    "requirements": [
                        {
                            "requirement_type": "administration",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "within 4 weeks prior to cycle 1, day 1",
                                "at any time during the study"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia.",
            "criterions": [
                {
                    "exact_snippets": "Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1",
                    "criterion": "adverse events from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN] or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN] or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1.",
                    "criterion": "treatment with systemic immunostimulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma.",
            "criterions": [
                {
                    "exact_snippets": "Patients with acute leukemias",
                    "criterion": "acute leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "accelerated/blast phase chronic myelogenous leukemia",
                    "criterion": "chronic myelogenous leukemia (accelerated/blast phase)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic lymphocytic leukemia",
                    "criterion": "chronic lymphocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Burkitt lymphoma",
                    "criterion": "Burkitt lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-secretory myeloma",
                    "criterion": "non-secretory myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.",
            "criterions": [
                {
                    "exact_snippets": "Severe infections within 4 weeks prior to cycle 1, day 1",
                    "criterion": "severe infections",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan.",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pneumonitis (including drug induced)",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_CT_scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)",
            "criterions": [
                {
                    "exact_snippets": "Malignancies other than the disease under study within 5 years prior to cycle 1, day 1",
                    "criterion": "history of other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": "malignancy other than the disease under study"
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent)",
                    "criterion": "prior malignancy risk and treatment outcome",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "expected outcome",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated or surgically treated with curative intent"
                        }
                    ]
                },
                {
                    "exact_snippets": "undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)",
                    "criterion": "active surveillance for specific cancers",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "active surveillance"
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": [
                                "chronic lymphocytic leukemia Rai Stage 0",
                                "prostate cancer with Gleason score =< 6 and PSA =< 10 mg/mL"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with past or resolved hepatitis B infection; defined as having a negative hepatitis B surface antigen (HBsAg) test and a positive anti-HBc (antibody to hepatitis B core antigen) antibody test, are eligible.",
            "criterions": [
                {
                    "exact_snippets": "negative hepatitis B surface antigen (HBsAg) test",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive anti-HBc (antibody to hepatitis B core antigen) antibody test",
                    "criterion": "anti-HBc (antibody to hepatitis B core antigen) antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.",
            "criterions": [
                {
                    "exact_snippets": "The use of inhaled corticosteroids ... is allowed.",
                    "criterion": "inhaled corticosteroids use",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "The use of ... mineralocorticoids (e.g., fludrocortisone) ... is allowed.",
                    "criterion": "mineralocorticoids use",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with orthostatic hypotension",
                    "criterion": "orthostatic hypotension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with ... adrenocortical insufficiency",
                    "criterion": "adrenocortical insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents. Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents.",
                    "criterion": "prior treatment with anti-PD-1, anti-PD-L1, or pathway targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4",
                    "criterion": "time since first dose of anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "> 6 weeks from the last dose",
                    "criterion": "time since last dose of anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)",
                    "criterion": "history of severe immune-related adverse effects from anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "history of severe immune-related adverse effects (CTCAE grade 3 or 4)",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Please Note:",
            "criterions": []
        },
        {
            "line": "* Measurable disease per RECIST v1.1 and/or per direct clinical measurements for primary tumors upon a variance between clinical and radiographic evaluation.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST v1.1",
                    "criterion": "measurable disease (RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease ... per direct clinical measurements for primary tumors upon a variance between clinical and radiographic evaluation",
                    "criterion": "measurable disease (direct clinical measurements for primary tumors)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "direct clinical measurements for primary tumors"
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "variance between clinical and radiographic evaluation"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Continued sexual activity in men** or women of childbearing potential*** who are unwilling to practice highly effective contraception during the study and until 6 months after the last dose of study drug (highly effective contraceptive measures include stable use of oral contraceptives such as combined estrogen and progestogen and progestogen only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; intrauterine hormone-releasing system [IUS]; bilateral tubal ligation; vasectomy, and sexual abstinence). (**Contraception is not required for men with documented vasectomy ***Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.)",
            "criterions": [
                {
                    "exact_snippets": "Continued sexual activity in men or women of childbearing potential who are unwilling to practice highly effective contraception during the study and until 6 months after the last dose of study drug",
                    "criterion": "sexual activity and contraception use",
                    "requirements": [
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "highly effective contraceptive measures include stable use of oral contraceptives such as combined estrogen and progestogen and progestogen only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; intrauterine hormone-releasing system [IUS]; bilateral tubal ligation; vasectomy, and sexual abstinence",
                    "criterion": "contraceptive method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "oral contraceptives (combined estrogen and progestogen)",
                                "progestogen only hormonal contraception",
                                "other prescription pharmaceutical contraceptives (for 2 or more menstrual cycles prior to screening)",
                                "intrauterine device (IUD)",
                                "intrauterine hormone-releasing system (IUS)",
                                "bilateral tubal ligation",
                                "vasectomy",
                                "sexual abstinence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Contraception is not required for men with documented vasectomy",
                    "criterion": "vasectomy status in men",
                    "requirements": [
                        {
                            "requirement_type": "vasectomy status",
                            "expected_value": "documented"
                        }
                    ]
                },
                {
                    "exact_snippets": "Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential",
                    "criterion": "postmenopausal status in women",
                    "requirements": [
                        {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation",
                    "criterion": "hysterectomy or tubal ligation status in women",
                    "requirements": [
                        {
                            "requirement_type": "hysterectomy status",
                            "expected_value": "documented"
                        },
                        {
                            "requirement_type": "tubal ligation status",
                            "expected_value": "documented"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}